-
1
-
-
84976479130
-
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
-
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
-
(2016)
Hepatology
, vol.64
, pp. 73-84
-
-
Younossi, Z.M.1
Koenig, A.B.2
Abdelatif, D.3
Fazel, Y.4
Henry, L.5
Wymer, M.6
-
2
-
-
0034831067
-
Nonalcoholic steatohepatitis
-
Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710–723.
-
(2001)
Gastroenterology
, vol.121
, pp. 710-723
-
-
Reid, A.E.1
-
3
-
-
79960029926
-
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
-
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 274-285
-
-
Vernon, G.1
Baranova, A.2
Younossi, Z.M.3
-
4
-
-
84926643436
-
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
-
Nakahara T, Hyogo H, Yoneda M et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014; 49: 1477–1484.
-
(2014)
J Gastroenterol
, vol.49
, pp. 1477-1484
-
-
Nakahara, T.1
Hyogo, H.2
Yoneda, M.3
-
5
-
-
85007162511
-
Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression
-
Seko Y, Sumida Y, Tanaka S et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatol Res 2017; 47: 1083–1092.
-
(2017)
Hepatol Res
, vol.47
, pp. 1083-1092
-
-
Seko, Y.1
Sumida, Y.2
Tanaka, S.3
-
6
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
7
-
-
85034766786
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
-
(2017)
N Engl J Med
, vol.377
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
-
8
-
-
84947998361
-
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
-
Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
-
(2016)
Diabetes Metab
, vol.42
, pp. 25-32
-
-
Leiter, L.A.1
Forst, T.2
Polidori, D.3
Balis, D.A.4
Xie, J.5
Sha, S.6
-
9
-
-
85008262665
-
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
-
Seko Y, Sumida Y, Tanaka S et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 2017; 47: 1072–1078.
-
(2017)
Hepatol Res
, vol.47
, pp. 1072-1078
-
-
Seko, Y.1
Sumida, Y.2
Tanaka, S.3
-
10
-
-
85021699331
-
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
-
Seko Y, Sumida Y, Sasaki K et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 2018; 53: 140–151.
-
(2018)
J Gastroenterol
, vol.53
, pp. 140-151
-
-
Seko, Y.1
Sumida, Y.2
Sasaki, K.3
-
11
-
-
85028766250
-
Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study
-
Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 2017; 87: 13–19.
-
(2017)
Curr Ther Res Clin Exp
, vol.87
, pp. 13-19
-
-
Tobita, H.1
Sato, S.2
Miyake, T.3
Ishihara, S.4
Kinoshita, Y.5
-
12
-
-
85042524553
-
Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies
-
Akuta N, Watanabe C, Kawamura Y et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 2017; 1: 46–52.
-
(2017)
Hepatol Commun
, vol.1
, pp. 46-52
-
-
Akuta, N.1
Watanabe, C.2
Kawamura, Y.3
-
13
-
-
85012306085
-
Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
-
Sumida Y, Seko Y, Yoneda M, Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res 2017; 47: 266–280.
-
(2017)
Hepatol Res
, vol.47
, pp. 266-280
-
-
Sumida, Y.1
Seko, Y.2
Yoneda, M.3
-
14
-
-
85040734374
-
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study
-
Shibuya T, Fushimi N, Kawai M et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab 2018; 20: 438–442.
-
(2018)
Diabetes Obes Metab
, vol.20
, pp. 438-442
-
-
Shibuya, T.1
Fushimi, N.2
Kawai, M.3
-
16
-
-
85033483636
-
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis
-
Ito K, Murotani K, Nakade Y et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol 2017; 32: 1922–1930.
-
(2017)
J Gastroenterol Hepatol
, vol.32
, pp. 1922-1930
-
-
Ito, K.1
Murotani, K.2
Nakade, Y.3
-
17
-
-
84937252875
-
Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease
-
Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776–784.
-
(2015)
J Gastroenterol
, vol.50
, pp. 776-784
-
-
Abe, M.1
Miyake, T.2
Kuno, A.3
-
18
-
-
70349546276
-
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease
-
Shah AG, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104–1112.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 1104-1112
-
-
Shah, A.G.1
Lydecker, A.2
Murray, K.3
-
19
-
-
84855390033
-
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
-
Sumida Y, Yoneda M, Hyogo H et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
-
(2012)
BMC Gastroenterol
, vol.12
, pp. 2
-
-
Sumida, Y.1
Yoneda, M.2
Hyogo, H.3
-
20
-
-
85046628830
-
The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study
-
Ishiba H, Sumida Y, Tanaka S et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol 2018. https://doi.org/10.1007/s00535-018-1474-y.
-
(2018)
J Gastroenterol
-
-
Ishiba, H.1
Sumida, Y.2
Tanaka, S.3
-
21
-
-
34247384560
-
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
-
Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–854.
-
(2007)
Hepatology
, vol.45
, pp. 846-854
-
-
Angulo, P.1
Hui, J.M.2
Marchesini, G.3
-
22
-
-
84979780774
-
Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score
-
Hayashi T, Saitoh S, Takahashi J et al. Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score. Hepatol Res 2017; 47: 455–464.
-
(2017)
Hepatol Res
, vol.47
, pp. 455-464
-
-
Hayashi, T.1
Saitoh, S.2
Takahashi, J.3
-
23
-
-
0030995737
-
Introduction of fast MR imaging in the assessment of hepatic steatosis
-
Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997; 15: 287–293.
-
(1997)
Magn Reson Imaging
, vol.15
, pp. 287-293
-
-
Fishbein, M.H.1
Gardner, K.G.2
Potter, C.J.3
Schmalbrock, P.4
Smith, M.A.5
-
24
-
-
79960266192
-
T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease
-
Pacifico L, Martino MD, Catalano C et al. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol 2011; 17: 3012–3019.
-
(2011)
World J Gastroenterol
, vol.17
, pp. 3012-3019
-
-
Pacifico, L.1
Martino, M.D.2
Catalano, C.3
-
25
-
-
85031712678
-
The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium–glucose cotransporter 2 inhibitor ipragliflozin
-
Takeda A, Irahara A, Nakano A et al. The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium–glucose cotransporter 2 inhibitor ipragliflozin. Intern Med 2017; 56: 2739–2744.
-
(2017)
Intern Med
, vol.56
, pp. 2739-2744
-
-
Takeda, A.1
Irahara, A.2
Nakano, A.3
-
26
-
-
40449095940
-
Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL
-
Kim H, Taksali SE, Dufour S et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 2008; 59: 521–527.
-
(2008)
Magn Reson Med
, vol.59
, pp. 521-527
-
-
Kim, H.1
Taksali, S.E.2
Dufour, S.3
-
27
-
-
67649205135
-
Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered
-
McPherson S, Jonsson JR, Cowin GJ et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009; 51: 389–397.
-
(2009)
J Hepatol
, vol.51
, pp. 389-397
-
-
McPherson, S.1
Jonsson, J.R.2
Cowin, G.J.3
-
28
-
-
77954757826
-
Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat signal separation in liver-fat quantification: comparison to liver biopsy
-
Fischer MA, Nanz D, Reiner CS et al. Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat signal separation in liver-fat quantification: comparison to liver biopsy. Invest Radiol 2010; 45: 465–470.
-
(2010)
Invest Radiol
, vol.45
, pp. 465-470
-
-
Fischer, M.A.1
Nanz, D.2
Reiner, C.S.3
-
29
-
-
84865759802
-
Liver fat quantification by dual-echo MR imaging outperforms traditional histopathological analysis
-
Fischer MA, Raptis DA, Montani M et al. Liver fat quantification by dual-echo MR imaging outperforms traditional histopathological analysis. Acad Radiol 2012; 19: 1208–1214.
-
(2012)
Acad Radiol
, vol.19
, pp. 1208-1214
-
-
Fischer, M.A.1
Raptis, D.A.2
Montani, M.3
-
30
-
-
84857871470
-
MRI steatosis grading: development and initial validation of a color mapping system
-
Qayyum A, Nystrom M, Noworolski SM, Chu P, Mohanty A, Merriman R. MRI steatosis grading: development and initial validation of a color mapping system. Am J Roentgenol 2012; 198: 582–588.
-
(2012)
Am J Roentgenol
, vol.198
, pp. 582-588
-
-
Qayyum, A.1
Nystrom, M.2
Noworolski, S.M.3
Chu, P.4
Mohanty, A.5
Merriman, R.6
-
31
-
-
85052836880
-
Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)
-
Kuchay MS, Krishan S, Mishra SK et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 2018; 41: 1801–1808.
-
(2018)
Diabetes Care
, vol.41
, pp. 1801-1808
-
-
Kuchay, M.S.1
Krishan, S.2
Mishra, S.K.3
-
32
-
-
84155188801
-
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease
-
Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77–85.
-
(2012)
Hepatology
, vol.55
, pp. 77-85
-
-
Kowdley, K.V.1
Belt, P.2
Wilson, L.A.3
-
33
-
-
79954442712
-
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
-
Sumida Y, Yoneda M, Hyogo H et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257–268.
-
(2011)
J Gastroenterol
, vol.46
, pp. 257-268
-
-
Sumida, Y.1
Yoneda, M.2
Hyogo, H.3
-
34
-
-
84945436270
-
Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients
-
Seko Y, Sumida Y, Tanaka S et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 2015; 45: E53–E61.
-
(2015)
Hepatol Res
, vol.45
, pp. E53-E61
-
-
Seko, Y.1
Sumida, Y.2
Tanaka, S.3
-
35
-
-
85038094859
-
Current and future pharmacological therapies for NAFLD/NASH
-
Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018; 53: 362–376.
-
(2018)
J Gastroenterol
, vol.53
, pp. 362-376
-
-
Sumida, Y.1
Yoneda, M.2
-
36
-
-
84947786115
-
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
-
Qiang S, Nakatsu Y, Seno Y et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
-
(2015)
Diabetol Metab Syndr
, vol.7
, pp. 104
-
-
Qiang, S.1
Nakatsu, Y.2
Seno, Y.3
-
37
-
-
85028772096
-
Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild/moderate hepatic impairment: a pharmacokinetic study
-
Samukawa Y, Sata M, Furihata K et al. Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild/moderate hepatic impairment: a pharmacokinetic study. Clin Pharmacol Drug Dev 2017; 6: 439–447.
-
(2017)
Clin Pharmacol Drug Dev
, vol.6
, pp. 439-447
-
-
Samukawa, Y.1
Sata, M.2
Furihata, K.3
-
38
-
-
84903557735
-
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
-
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245–1255.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1245-1255
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
Ubukata, M.4
Sakai, S.5
Samukawa, Y.6
|